{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:09:00Z","timestamp":1781701740449,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Medical Center of Key Programs for Female Reproductive Diseases","award":["2017ZZ01016"],"award-info":[{"award-number":["2017ZZ01016"]}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC12015117"],"award-info":[{"award-number":["SHDC12015117"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Although HPV testing and cytology detection are successful for cervical screening in China, additional procedures are urgently required to avoid misdiagnosis and overtreatment. In this multicenter study, we collected cervical samples during screening in clinics. A total of 588 women with HPV16\/18+ and\/or cytology result \u2265HSIL+ (high-grade squamous intraepithelial lesion or worse) were referred to colposcopy for pathological diagnosis. Methylation of S5 was quantified by pyrosequencing.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The S5 classifier separates women with \u2265HSIL+ from &lt;HSIL with a high area under the curve (AUC) of 0.86 (95% CI 0.840\u20130.910). The cutoff of 2.85 was conducted in our study. Remarkably, all cancer cases (<jats:italic>n<\/jats:italic> = 67) were detected by S5. The sensitivity of S5 for \u201c\u2265HSIL+\u201d was 89.1% (95% CI 86.2\u201392.4%), and the specificity was 76.6% (95% CI 72.2\u201378.9%). S5 could reduce unnecessary colposcopy referrals by 74% (95% CI 71.3\u201378.1%) with virtually no loss of sensitivity for HSIL+, and the follow-up data support the utility of the S5 classifier.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The S5 classifier with high sensitivity and specificity provided increasing diagnostic information for women with HPV16\/18+ and\/or cytology results and could reduce the numerous unnecessary colposcopy referrals and avoid overtreatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13148-020-00849-x","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T17:07:05Z","timestamp":1587488825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of a methylation classifier for predicting pre-cancer lesion among women with abnormal results between HPV16\/18 and cytology"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuan-Yuan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Qin","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,21]]},"reference":[{"key":"849_CR1","unstructured":"Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging. Journal of BUON. 2016:21(2)."},{"key":"849_CR2","doi-asserted-by":"crossref","unstructured":"et al. B Passamonti, D Gustinucci, P Giorgi Rossi, E Cesarini, S Bulletti, A Carlani, Cervical human papilloma virus (HPV) DNA primary screening test: results of a population-based screening programme in central Italy. J Med Screen. 2017:24(3).","DOI":"10.1177\/0969141316663580"},{"key":"849_CR3","doi-asserted-by":"crossref","unstructured":"Torre LA, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians. 2012:65(2).","DOI":"10.3322\/caac.21262"},{"key":"849_CR4","doi-asserted-by":"crossref","unstructured":"Clarke M, Gradissimo A, Schiffman M, Lam J, Sollecito C, Fetterman B, et al. Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women. Clin Cancer Res. 2018:24(9).","DOI":"10.1158\/1078-0432.CCR-17-3251"},{"key":"849_CR5","doi-asserted-by":"crossref","unstructured":"Ahmad A, Raish M, Shahid M, Batra S, Batra V, Husain S. The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer. Cancer Biomark. 2017;19(4).","DOI":"10.3233\/CBM-160060"},{"key":"849_CR6","doi-asserted-by":"crossref","unstructured":"Kocsis A, Takacs T, Jeney C, Schaff Z, Koiss R, Jaray B, et al. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. Clin Chem Lab Med. 2017;50(10).","DOI":"10.1002\/ijc.30534"},{"key":"849_CR7","doi-asserted-by":"crossref","unstructured":"Pefoyo AK, Wang L, Gao J, Kupets R. Are women who exit colposcopy without treatment at elevated risk for cervical cancer? J Low Genit Tract Dis. 2017;21(1).","DOI":"10.1097\/LGT.0000000000000265"},{"key":"849_CR8","doi-asserted-by":"crossref","unstructured":"Leeman A, Ebisch R, Kasius A, Bosgraaf R, Jenkins D, Van De Sandt M, et al. Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16\/18 and FAM19A4\/miR124-2 methylation. Gynecol Oncol. 2018;151(2).","DOI":"10.1016\/j.ygyno.2018.09.006"},{"key":"849_CR9","doi-asserted-by":"crossref","unstructured":"L Torre, R Siegel, E Ward, A Jemal, Global cancer incidence and mortality rates and trends--an update. Cancer Epidemiol Biomarkers Prev. 2016:25(1).","DOI":"10.1158\/1055-9965.EPI-15-0578"},{"key":"849_CR10","doi-asserted-by":"crossref","unstructured":"F Vink, Cjlm Meijer, G Clifford, M Poljak, A Ostrbenk, K Petry et al: FAM19A4\/miR124-2 methylation in invasive cervical cancer: a retrospective cross-sectional worldwide study. International Journal of Cancer 2019, Aug 7.","DOI":"10.1002\/ijc.32614"},{"key":"849_CR11","doi-asserted-by":"crossref","unstructured":"Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. Journal of the National Cancer Institute. 2012;204(22).","DOI":"10.1093\/jnci\/djs425"},{"key":"849_CR12","doi-asserted-by":"crossref","unstructured":"S Wilting, Ra Van Boerdonk, Fe Henken, Cj Meijer, B Diosdado, Ga Meijer et al: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Molecular Cancer 2010, 2010 Jun 26;9.","DOI":"10.1186\/1476-4598-9-167"},{"key":"849_CR13","doi-asserted-by":"crossref","unstructured":"Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014:35(6).","DOI":"10.1007\/s13277-014-1737-z"},{"key":"849_CR14","doi-asserted-by":"crossref","unstructured":"Heichman K, Warren J. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clinical chemistry and laboratory medicine. 2012;50(10).","DOI":"10.1515\/cclm-2011-0935"},{"key":"849_CR15","doi-asserted-by":"crossref","unstructured":"Lorincz A, Brentnall A, Vasiljevic N, Scibior-Bentkowska D, Castanon A, Fiander A, et al. HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. International Journal of Cancer. 2013:1333.","DOI":"10.1002\/ijc.28050"},{"key":"849_CR16","doi-asserted-by":"crossref","unstructured":"De Strooper L, Berkhof J, Steenbergen R, Lissenberg-Witte BI, Snijders P, Meijer C, et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4\/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow-up. International Journal of Cancer. 2018:1436.","DOI":"10.1002\/ijc.31539"},{"key":"849_CR17","doi-asserted-by":"crossref","unstructured":"De Strooper L, Verhoef V, Berkhof J, Hesselink A, De Bruin H, Van Kemenade F, et al. Validation of the FAM19A4\/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women. Gynecol Oncol. 2016:141(2).","DOI":"10.1016\/j.ygyno.2016.02.012"},{"key":"849_CR18","doi-asserted-by":"crossref","unstructured":"Hernandez-Lopez R, Lorincz A, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16\/18 genotyping. Clinical Epigenetics. 2019:111.","DOI":"10.1186\/s13148-019-0743-9"},{"key":"849_CR19","unstructured":"Ar B, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J, Cuzick J, et al. HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and {EPB41L3} methylation classifier. Cancer Biomark. 2015;155."},{"key":"849_CR20","doi-asserted-by":"crossref","unstructured":"Cook D, Krajden M, Brentnall A, Gondara L, Chan T, Law JH, et al. Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial. International Journal of Cancer. 2019;144(10).","DOI":"10.1002\/ijc.31976"},{"key":"849_CR21","doi-asserted-by":"crossref","unstructured":"Lorincz A, Brentnall A, Scibior-Bentkowska D, Reuter C, Banwait R, Cadman L, et al. Validation of a DNA methylation HPV triage classifier in a screening sample. Int J Cancer. 2016:13811.","DOI":"10.1002\/ijc.30008"},{"key":"849_CR22","doi-asserted-by":"crossref","unstructured":"Hernandez-Lopez R, Lorincz ATA-OHOO, Torres-Ibarra L, Reuter C, Scibior-Bentkowska D, Warman R, et al. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16\/18 genotyping. Clin Epigenetics. 2019:111.","DOI":"10.1186\/s13148-019-0743-9"},{"key":"849_CR23","unstructured":"Chen Y, Rl H, Yk H, Liao Y, Ph S, Wang H, et al. Methylomics analysis identifies epigenetically silenced genes and implies an activation of beta-catenin signaling in cervical cancer. International Journal of Cancer. 2014:1351."},{"key":"849_CR24","unstructured":"Lai HC, Ou YC, Chen TC, Huang HJ, Cheng YM, Chen CH, Chu TY, Hsu ST, Liu CB, Hung YC, et al. PAX1\/SOX1 DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic Oncology Group (TGOG) study. Cancer Medicine. 2014;34."},{"key":"849_CR25","doi-asserted-by":"crossref","unstructured":"Pun PB, Liao YP, Su PH, Wang HC, Chen YC, Hsu YW, et al. Triage of high-risk human papillomavirus-positive women by methylated POU4F3. Clinical Epigenetics. 2015;217.","DOI":"10.1186\/s13148-015-0122-0"},{"key":"849_CR26","doi-asserted-by":"crossref","unstructured":"Hesselink AT, Heideman DA, Steenbergen RD, Coup\u00e9 VM, Overmeer RM, Rijkaart D, Berkhof J, et al. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clinical Cancer Research. 2011:1517.","DOI":"10.1158\/1078-0432.CCR-10-2548"},{"key":"849_CR27","doi-asserted-by":"crossref","unstructured":"Eijsink JJ, Lendvai \u00c1, Deregowski V, Klip HG, Verpooten G, Dehaspe L, de Bock GH, et al. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. International Journal of Cancer. 2012:15130.","DOI":"10.1002\/ijc.26326"},{"key":"849_CR28","doi-asserted-by":"crossref","unstructured":"Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al. A promising DNA methylation signature for the triage of high-risk human papillomavirus DNA-positive women. PLoS One. 2014;199.","DOI":"10.1055\/s-0034-1388604"},{"key":"849_CR29","doi-asserted-by":"crossref","unstructured":"Hesselink AT, Heideman DA, Steenbergen RD, G\u00f6k M, van Kemenade FJ, Wilting SM, Berkhof J, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. International Journal of Cancer. 2014:15135.","DOI":"10.1002\/ijc.28723"},{"key":"849_CR30","doi-asserted-by":"crossref","unstructured":"Schmitz MA-OHOO, Eichelkraut K, Schmidt D, Zeiser I, Hilal Z, Tettenborn Z, et al. Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages. BMC Cancer. 2018:181.","DOI":"10.1186\/s12885-018-5125-8"},{"key":"849_CR31","unstructured":"Ma C, Luhn P, Gage J, Bodelon C, Dunn S, Walker J. Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. International Journal of Cancer. et al, 2017;141(4):4."},{"key":"849_CR32","doi-asserted-by":"crossref","unstructured":"Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG. 2010;117(3).","DOI":"10.1111\/j.1471-0528.2009.02438.x"},{"key":"849_CR33","doi-asserted-by":"crossref","unstructured":"K Van Velthoven, W Poppe, H Verschuere, M Arbyn: Pregnancy outcome after cervical conisation: a 2nd retrospective cohort study in the Leuven University Hospital. Eur J Obstet Gynecol Reprod Biol 2017, 2017 sep;216.","DOI":"10.1016\/j.ejogrb.2017.06.043"},{"key":"849_CR34","doi-asserted-by":"crossref","unstructured":"Wentzensen N, Schiffman M, Mi S, Mj K, Rb P, Km S, et al. ASCCP colposcopy standards: risk-based colposcopy practice. J Low Genit Tract Dis. 2017:214.","DOI":"10.1097\/LGT.0000000000000334"},{"key":"849_CR35","doi-asserted-by":"crossref","unstructured":"Y Tian, W Yuan, Y Liou, C Yeh, L Cao, Y Kang et al: Utility of gene methylation analysis, cytological examination, and HPV-16\/18 genotyping in triage of high-risk human papilloma virus-positive women. Oncotarget 2018, 8(37).","DOI":"10.18632\/oncotarget.19459"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-020-00849-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-020-00849-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T23:52:48Z","timestamp":1618962768000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-020-00849-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1186\/s13148-020-00849-x","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"8 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of our hospitals, and the study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice. Oral and written informed consents were obtained from the patients or their guardians before the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}